Press releases

Boston Scientific (NYSE: BSX) has launched the Resonate™ family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems featuring the...

Boston Scientific (NYSE: BSX) today announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study evaluating the performance of the...

Boston Scientific (NYSE: BSX) today announced results from a three year follow-up cohort in its Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma...

Boston Scientific Corporation (NYSE: BSX) will participate in the Morgan Stanley Global Healthcare Conference on September 12, 2017 in New York City. Mike Mahoney, chairman and chief executive...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo Healthcare Conference on September 7, 2017 in Boston. Susie Lisa, vice president, Investor Relations, will...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Canaccord Genuity Growth Conference on August 9, 2017 in Boston. Boston Scientific investor relations representatives,...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.257 billion during the second quarter ended June 30, 2017. This represents growth of 6 percent on a reported basis and 7 percent on...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2017 on Thursday, July 27, 2017 at

Boston Scientific Corporation (NYSE: BSX) is hosting a meeting with the investment community today in New York City to provide an overview of its business and long-term growth strategies. Chairman...

Boston Scientific (NYSE: BSX) has received CE mark for the Vercise™ Gevia™ Deep Brain Stimulation (DBS) System*, a rechargeable, magnetic resonance (MR) conditional device indicated for the...

Boston Scientific (NYSE: BSX) today announced positive results from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma (PAS2) study evaluating...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2017 UBS Global Healthcare Conference on Tuesday, May 23, 2017 in New York City. Susie Lisa, vice president, investor...

Boston Scientific (NYSE: BSX) today announced positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program, in Paris. Data from the study demonstrated...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter...

Boston Scientific (NYSE: BSX) today announced positive safety and efficacy rates of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry presented during a...

New analyses from the Boston Scientific Corporation (NYSE: BSX) sponsored PLATINUM Diversity study underscore the need for greater understanding of the clinical and nonclinical barriers that can...

Boston Scientific (NYSE: BSX) today announced results from the U.S. post-market approval study evaluating 'real-world' patients implanted with the Subcutaneous Implantable Defibrillator (S-ICD)...

Boston Scientific (NYSE: BSX) today announced the schedule of key data presentations, including four late-breaking clinical trials, that will be featured at the annual EuroPCR Scientific Program,...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Resonate™ family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization...

Boston Scientific (NYSE: BSX) today announced the schedule of key data presentations, including two late-breaking clinical trials, that will be featured at the 38th Annual Scientific Sessions of...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2017 Healthcare Conference on Thursday, May 18, 2017 in Las Vegas. Susie Lisa, vice...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.160 billion during the first quarter ended March 31, 2017. This represents growth of 10 percent compared to the prior year period on...

Boston Scientific (NYSE: BSX) has initiated a worldwide study that will evaluate the survival benefit of patients treated with the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD)...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2017 on Thursday, April 27,...

Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter...

Today, the National Institute for Health and Care Excellence (NICE) issued medical technology guidance recommending the use of Boston Scientific Corporation (NYSE: BSX) cardiac resynchronization...

Boston Scientific Corporation (NYSE: BSX) today announced the German District Court of Düsseldorf has determined that Edwards Lifesciences Corporation and its German subsidiary's Sapien 3™...

Boston Scientific Corporation (NYSE: BSX) will participate in the Barclays Global Healthcare Conference on March 15 in Miami Beach, Florida. Mike Mahoney, chairman and chief executive officer, and...

Boston Scientific Corporation (NYSE: BSX) today announced six finalists in its second annual Connected Patient Challenge, an open competition focused on turning big data into actionable...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Cowen and Company 37th Annual Healthcare Conference on Tuesday, March 7, 2017 in Boston. Dan Brennan, executive vice...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2017 RBC Capital Markets Global Healthcare Conference on Thursday, February 23, 2017 in New York. Dan Brennan,...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.191 billion during the fourth quarter ended December 31, 2016. This represents growth of 11 percent compared to the prior year...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the LEERINK Partners 6th Annual Global Healthcare Conference on February 15, in New York. Susie Lisa, vice president,...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter ended December 31, 2016 on Thursday, February 2, 2017, at 8:00 a.m....

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 in San Francisco. Mike Mahoney, chairman and...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of certain manufacturing assets and capabilities of the Neovasc, Inc., (NASDAQ: NVCN) (TSX: NVC) advanced...

MARLBOROUGH, Mass., December 5, 2016 — Boston Scientific (NYSE: BSX) has been recognized for the third consecutive year as a “Best Place to Work” by the Human Rights Campaign Foundation. The...

Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire certain manufacturing assets and capabilities of the Neovasc, Inc., (NASDAQ: NVCN) (TSX: NVC) advanced...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Citi 2016 Global Healthcare Conference on December 7 in New York City. Dan Brennan, executive vice president & chief...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of EndoChoice Holdings, Inc. (NYSE: GI). With the completion of the acquisition, EndoChoice will become part...

Boston Scientific today announced that its Cork, Ireland manufacturing facility has received the 2016 Shingo Prize for Excellence in Manufacturing from the Shingo Institute, part of the Jon M....

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 28th Annual Piper Jaffray Healthcare Conference on November 29 in New York City. Jeff Mirviss, senior vice president &...

Boston Scientific (NYSE: BSX) today announced results from the first clinical trial evaluating the performance of the HeartLogic™ Heart Failure Diagnostic Service to predict impending heart...

Boston Scientific (NYSE: BSX) has acquired the gynecology and urology portfolio of Distal Access, LLC, a Salt Lake City based company that designs minimally invasive medical devices. The portfolio...

MARLBOROUGH, Mass., (Nov. 8, 2016) – Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launch of the Dakota™ Nitinol Stone Retrieval Device with OpenSure™...

Boston Scientific Corporation (NYSE: BSX) today announced that its wholly owned merger subsidiary, Falcon Merger Corp., has extended its previously announced tender offer for all shares of...

Boston Scientific (NYSE: BSX) today announced the acquisition of the LumenR™ Tissue Retractor System from LumenR LLC, a privately held Newark, California based company. The LumenR Tissue...

Boston Scientific (NYSE: BSX) announced initial U.S. commercial performance results of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device today during a late-breaking clinical trial...

As part of the commitment to support health equity for all patients, Boston Scientific Corporation (NYSE: BSX) sponsored the PLATINUM Diversity study to evaluate the clinical outcomes of the...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Stifel 2016 Healthcare Conference on November 15 in New York City. Dan Brennan, executive vice president & chief...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.105 billion during the third quarter ended September 30, 2016, compared to the company's guidance range for the quarter of $2.035 to...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 25th Annual Credit Suisse Healthcare Conference on November 7, in Scottsdale, Arizona. Joe Fitzgerald, executive vice...

Boston Scientific (NYSE: BSX) today announced key data which will be presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular...

Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Resolution 360™ Clip, a novel technology designed to improve hemostatic clipping by providing physicians controlled...

Marlborough, Mass. October 13, 2016) -- Boston Scientific Corporation (NYSE: BSX) today announced a worldwide call for submissions to the second annual Boston Scientific Connected Patient...

Boston Scientific Corporation (NYSE: BSX) announced today that Professor Ian Meredith AM will join the company as executive vice president and global chief medical officer in January 2017. In his...

Boston Scientific Corporation (NYSE: BSX) today announced that its wholly owned merger subsidiary, Falcon Merger Corp., has launched its previously announced tender offer for all shares of...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2016 on Wednesday, October...

Boston Scientific (NYSE: BSX) and EndoChoice Holdings, Inc. (NYSE: GI) today announced the companies have entered into a definitive agreement under which Boston Scientific has agreed to acquire...

Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the LOTUS Edge™ Valve System, the company's next generation transcatheter aortic valve implantation (TAVI) technology. The...

Boston Scientific Corporation (NYSE: BSX) will participate in the Morgan Stanley Global Healthcare Conference on September 13, in New York City. Mike Mahoney, chief executive officer, and Dan...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo Healthcare Conference on September 7, in Boston. Mike Mahoney, chief executive officer, Dan Brennan,...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 36th Annual Canaccord Genuity Growth Conference on August 11 in Boston and the 2016 Wedbush PacGrow Healthcare...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.126 billion during the second quarter ended June 30, 2016, compared to the company's guidance range for the quarter of $2.010 to...

Boston Scientific Corporation (NYSE: BSX) today announced that it has acquired Cosman Medical, Inc., a privately held Burlington, Mass. manufacturer of radiofrequency ablation (RFA) systems. The...

Boston Scientific Corporation (NYSE: BSX) announced today the election of Yoshiaki Fujimori to its board of directors, effective immediately. Yoshiaki Fujimori is an adviser to the LIXIL Group...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2016 on Thursday, July 28, 2016 at

Boston Scientific Corporation (NYSE: BSX) today announced that its GreenLight XPS™ Laser Therapy System, used for the treatment of prostatic enlargement, known as benign prostatic hyperplasia...

Boston Scientific Corporation (NYSE: BSX) today announced a global restructuring program to build on the progress the company has made in executing long-term growth strategies and bringing...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs Global Healthcare Conference on June 9 in Rancho Palos Verdes. Dan Brennan, executive vice president and...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Jefferies 2016 Healthcare Conference on June 7, in New York City. Susie Lisa, vice president, Investor Relations, will...

Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Precision Montage™ MRI Spinal Cord Stimulator (SCS) System after receiving approval from the U.S. Food and Drug...

Boston Scientific (NYSE: BSX) today announced the schedule of key data that will be featured at the annual EuroPCR Scientific Program, May 17-20 in Paris. Data from the 1,000-patient EWOLUTION...

Boston Scientific (NYSE: BSX) today announced results from the largest post-market registry for the Subcutaneous Implantable Defibrillator (S-ICD) System. Data collected from the EFFORTLESS study...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for two catheters that can be used with the Rhythmia™ Mapping System. The IntellaNav™ XP and the...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2016 Health Care Conference on May 12, in Las Vegas. Dan Brennan, executive vice...

Boston Scientific (NYSE: BSX) today announced key data, including one late-breaking clinical trial, that will be featured at the 37th Annual Scientific Sessions of the Heart Rhythm Society (HRS)...

Boston Scientific Corporation (NYSE: BSX) generated sales of $1.964 billion during the first quarter ended March 31, 2016, compared to the company's guidance range for the quarter of $1.890 to...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for a suite of products deemed safe for use in a magnetic resonance imaging (MRI) environment. The...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Deutsche Bank 41st Annual Health Care Conference on May 5, in Boston. Dan Brennan, executive vice president and chief...

Boston Scientific (NYSE: BSX) has received CE Mark approval for the new EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance (MR) conditional labeling...

Boston Scientific (NYSE: BSX) has initiated a global, voluntary recall of all models of its Fetch™ 2 Aspiration Catheter, a thrombectomy catheter used during procedures to remove small blood...

Boston Scientific does not use “counterfeit” or “adulterated” materials in our medical devices. The company rejects the allegations in the petition to the Food and Drug Administration...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2016 on Wednesday, April 27,...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 15th Annual Needham Healthcare Conference on April 12, in New York City. Susie Lisa, vice president, Investor...

Boston Scientific (NYSE: BSX) today announced key data presentations spanning its interventional cardiology, rhythm management and structural heart portfolios, that will be featured at the...

Boston Scientific Corporation (NYSE: BSX) today announced the launch of the AXIOS™ Stent and Electrocautery Enhanced Delivery System to help physicians manage two serious complications from...

Boston Scientific Corporation (NYSE: BSX) and Mayo Clinic today announced a continuing collaboration where the two organizations share intellectual property and stimulate the rapid development of...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Blazer™ Open-Irrigated (OI) radiofrequency ablation catheter. The Blazer OI catheter has been...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Barclays Global Health Care Conference on March 15, in Miami Beach. Dan Brennan, executive vice president and chief...

Boston Scientific Corporation (NYSE: BSX) announced today a number of changes to the leadership and membership of its Board of Directors. Pete M. Nicholas, the company's co-founder and chairman of...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Cowen & Co. 36th Annual Health Care Conference on March 8, in Boston. Dan Brennan, executive vice president and chief...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the ACUITY™ X4 Quadripolar Left Ventricular (LV) leads. The FDA approval of the quadripolar leads,...

Boston Scientific (NYSE: BSX) today announced that the Eluvia™ Drug-Eluting Vascular Stent System has received CE Mark and is commencing commercialization immediately in the European Union and...

Boston Scientific Corporation (NYSE: BSX) announced the Centers for Medicare and Medicaid Services (CMS) will cover percutaneous left atrial appendage closure (LAAC) therapy under specific...

Boston Scientific Corporation (NYSE: BSX) generated sales of $1.978 billion during the fourth quarter ended December 31, 2015. This represents 10 percent operational revenue growth (constant...

MARLBOROUGH, Mass. (February 1, 2016) – Boston Scientific Corporation (NYSE: BSX) today announced that Bronchial Thermoplasty (BT) delivered by the Alair™ System is now available to Tufts...

Boston Scientific Corporation (NYSE: BSX) and Accenture (NYSE: ACN) have developed a cloud-based, data-driven digital health solution for hospitals that is designed to help improve patient...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Leerink Partners 5th Annual Global Healthcare Conference on February 10, in New York City. Dan Brennan, executive vice...